louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04758689: Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients
Official title: Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-02-17
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Studying the effect of laser acupuncture on geriatric patients with rheumatoid arthritis


Eligibility criteria: Inclusion Criteria:

* Patients referred from physician (immunologist) diagnosed with rheumatoid arthritis.

Exclusion Criteria:

* Patients having the disease overlapping with other connective tissue diseases, such as systematic lupus erythromatosus and systematic sclerosis.
* History of malignancies.

Primary outcomes:
measure: Interleukin 6 (IL-6)
timeFrame: Baseline
measure: Interleukin 6 (IL-6)
timeFrame: 4 weeks
measure: Malondialdehyde (MDA)
timeFrame: Baseline
measure: Malondialdehyde (MDA)
timeFrame: 4 weeks
measure: Adenosine Triphosphate (ATP)
timeFrame: Baseline
measure: Adenosine Triphosphate (ATP)
timeFrame: 4 weeks
measure: C-Reactive Protein (CRP)
timeFrame: Baseline
measure: C-Reactive Protein (CRP)
timeFrame: 4 weeks
Secondary outcomes:
measure: Rheumatoid Arthritis Quality of Life (RAQoL)
timeFrame: Baseline
measure: Rheumatoid Arthritis Quality of Life (RAQoL)
timeFrame: 4 weeks
measure: Health Assessment Questionnaire (HAQ)
timeFrame: Baseline
measure: Health Assessment Questionnaire (HAQ)
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: A. Sedky
Study officials:
References:
citation: Adly AS, Adly AS, Adly MS. Effects of laser acupuncture tele-therapy for rheumatoid arthritis elderly patients. Lasers Med Sci. 2022 Feb;37(1):499-504. doi: 10.1007/s10103-021-03287-0. Epub 2021 Mar 19.
Clinical trial NCT06145789: The Use of Standing Powered Wheelchairs in Spinal Cord Injury
Official title: The Use of Standing Powered Wheelchairs in Individuals With Spinal Cord Injury
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spinal Cord Injuries
Keywords: standing powered wheelchair
spinal cord injury
satisfaction
secondary complication
Lead sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Sponsor class: OTHER
First posted: 2023-11-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with spinal cord injury who were prescribed a standing powered wheelchair at a tertiary hospital

Brief summary: The purpose of this study was to explore the experiences of standing powered wheelchair users with spinal cord injury.

Detailed description: There is limited research exploring the comfort, satisfaction, adverse effects, need for repair, and benefit in terms of secondary complications in standing powered wheelchair users with spinal cord injury.

The purpose of this study was to explore the experiences of standing powered wheelchair users with spinal cord injury.

Eligibility criteria: Inclusion Criteria:

* Ages 18-70
* Post-spinal cord injury period \> 1 year

Exclusion Criteria:

- Having cognitive impairment

Primary outcomes:
measure: Wheelchair satisfaction
timeFrame: through study completion, an average of one month
measure: Wheelchair comfort
timeFrame: through study completion, an average of one month
measure: Wheelchair repair
timeFrame: through study completion, an average of one month
measure: Adverse and positive experiences
timeFrame: through study completion, an average of one month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Study officials:
affiliation: Ankara Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
name: Merve Örücü Atar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03566589: Effects of PS128 on Parkinsonian Symptoms
Official title: Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Lead sponsor: Professor Lu Neurological Clinic
Sponsor class: OTHER
First posted: 2018-06-25
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.

Detailed description: This study is designed to examine the extent to which L. plantarum PS128 can improve symptoms in PD patients. L. plantarum PS128 is a psychobiotic that regulates the level of dopamine in specific brain regions. Patients with PD will receive PS128 treatment for 12 weeks. Symptoms of PD will be clinically evaluated before and after the treatment, and the results will be compared.

Eligibility criteria: Inclusion Criteria:

* Between ages of 40-80 years old
* Diagnosed as a patient with Parkinson's disease of modified Hoehn and Yahr Stage between 1 and 2.5 as rated during an "on" period

Exclusion Criteria:

* Patients on antibiotics within the preceding one month
* Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
* Have current or history of inflammatory bowel disease
* Have history of cancer
* Have undergone surgery of liver, bladder, or gastrointestinal tract
* Known allergy to probiotics
* Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
* Have received deep brain stimulation
* Patients receiving artificial enteral or intravenous nutrition

Primary outcomes:
measure: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 12 Assessed On Medication
timeFrame: Baseline to Week 12
Secondary outcomes:
measure: Change in Nonmotor Symptoms: 30-item Screening Questionnaire (NMS-Quest) Score From Baseline to Week 12 Assessed On Medication
timeFrame: to Week 12 Assessed On Medication
measure: Change in Patient Global Impression of Change (PGIC) Score From Baseline to Week 12 Assessed On Medication
timeFrame: to Week 12 Assessed On Medication
Other outcomes:
Locations:
city: Taoyuan City
country: Taiwan
facility: Professor Lu Neurological Clinic
state: Guishan Dist.
Study officials:
References:
Clinical trial NCT03846089: Retrograde Reperfusion Versus Antegrade Liver Transplant Reperfusion
Official title: A Propensity Score Matched Pair Analysis of Retrograde Reperfusion Versus Antegrade Liver Transplant Reperfusion
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Liver Transplant Failure
Lead sponsor: London Health Sciences Centre
Sponsor class: OTHER
First posted: 2019-02-19
Enrollment: 0
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who have undergone transplantation of the liver at LHSC.

Brief summary: A retrospective cohort analysis was performed comparing patients that had intra operative antegrade liver reperfusions versus patients that had retrograde liver perfusion.

Detailed description: A retrospective cohort analysis was performed comparing patients that had intra operative antegrade liver reperfusions versus patients that had retrograde liver perfusion. Antegrade Reperfusion(ATR) group: after completing the caval replacement or piggy-back, for IVC anastomosis, Portal vein (PV) anastomosis was done with a running suture as normal fashion, then it was followed by the removal the clamps, starting by the supra hepatic VC, followed by the PV clamp and finally the infrahepatic VC. It was followed by arterial anastomosis and the biliary anastomosis (duct-to-duct if possible). Retrograde group (RETR): after completing the piggyback the IVC was declamped immediately and retrograde low pressure reperfusion of the graft with low oxygenated venous blood was established. Central venous pressure was intended to be higher than in 8 mmHg to enable appropriate retrograde reperfusion in the transplanted liver. Significant venous backflow via portal vein appears immediately after declamping. Venous bleeding from the liver except portal backflow was stopped immediately after declamping the venous anastomosis, as appropriate. Portal vein anastomosis was performed using running suture. It was followed by arterial anastomosis and the biliary anastomosis (duct-to-duct if possible). The endpoints are patient survival and graft survival at 1, 3,5, 10 years post liver transplantation in both groups. To adjust for a selection bias, we will perform a propensity score analysis.

Eligibility criteria: Inclusion Criteria:

* all liver transplantations between 1 Jan 2002 and 31 Dec 2005

Exclusion Criteria:

* liver retransplantation
* multiorgan transplantation
* ABO incompatible transplantation

Primary outcomes:
measure: Graft survival
timeFrame: From date of transplantation until the date of next transplantation or date of death from any cause, whichever came first, assessed up to 300 months
Secondary outcomes:
measure: Patient survival
timeFrame: From date of transplantation until the date of death from any cause assessed up to 300 months
Other outcomes:
Locations:
Study officials:
affiliation: London Health Sciences Center
name: Vivian McAlister
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01741389: The Role of Melatonin in the Regulation of Blood Coagulation
Official title: The Role of Melatonin in the Regulation of Blood Coagulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Spinal Cord Injured, Tetraplegia
Keywords: Circadian variation, hemostasis, melatonin, tetraplegia
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: Sunnaas Hospital
name: Oslo University Hospital
First posted: 2012-12-04
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The main aim is to examine the influence of daylight and melatonin on the temporal variations of hemostatic factors with key roles in the hemostatic process and its regulation. Particular emphasis will be on exploring the role of melatonin in hemostasis by comparing subjects with tetraplegia with able-bodied control subjects.


Eligibility criteria: Inclusion Criteria:

Intervention group:

* A diagnosis of tetraplegia for at least 2 years, and otherwise healthy.
* Must not use drugs permanently (except anti-spasmolytics).
* Must be able to swallow tablets.
* Must give written consent to participate.

Control group:

* Must be healthy.
* Must not use drugs permanently.
* Must give written consent to participate.

Exclusion Criteria:

Both groups:

* Those with acute or chronic co-morbidity.
* Unable to cooperate.
* Not provided written consent to participate.

Primary outcomes:
measure: Circadian variation of hemostatic factors
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Nesodden
country: Norway
facility: Sunnaas Hospital
Study officials:
References:
citation: Dahm A, Osterud B, Hjeltnes N, Sandset PM, Iversen PO. Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation? J Thromb Haemost. 2006 Aug;4(8):1840-2. doi: 10.1111/j.1538-7836.2006.02048.x. No abstract available.
citation: Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Osterud B, Sandset PM, Iversen PO. Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul Fibrinolysis. 2011 Jun;22(4):254-9. doi: 10.1097/MBC.0b013e3283442ce2.
citation: Dahm AE, Iversen PO, Hjeltnes N, Sandset PM. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. Thromb Res. 2006;118(2):281-7. doi: 10.1016/j.thromres.2005.07.021. Epub 2005 Aug 31.
Clinical trial NCT04324489: DAS181 for Severe COVID-19: Compassionate Use
Official title: DAS181 for Severe COVID-19: Compassionate Use
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Keywords: COVID-19
SARS-CoV-2
DAS181
Hypoxemia
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
Collaborators: name: Ansun Biopharma, Inc.
First posted: 2020-03-27
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.

Detailed description: Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the first day of administration.

From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml) nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg (3.5m1) DAS181 should be delivered with about 12-hour interval.

Eligibility criteria: Key Inclusion Criteria:

1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens
2. Hypoxemic
3. Severe COVID-19
4. If female, subject must not be pregnant or nursing.
5. Non-vasectomized males are required to practice effective birth control methods
6. Capable of understanding and complying with procedures as outlined in the protocol as judged by the Investigator and able to sign informed consent form prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

1. ALT or AST\> 8 x ULN
2. (ALT or AST\> 3 x ULN) and (Total bilirubin\> 2.5 x ULN or INR\> 2.0 x ULN)
3. Female subjects who have a positive pregnancy test and are breastfeeding
4. Subjects using any other investigational antiviral drugs during the hospitalization before enrollment.
5. Subjects participating in other clinical trials
6. Subjects may be transferred to a non-participating hospital within 72 hours
7. People who cannot cooperate well due to mental illness, have no self-control, and cannot express clearly
8. Severe underlying diseases affecting survival
9. Critical COVID-19 requiring mechanical ventilator at the time enrolled

Primary outcomes:
measure: Improved clinical status
timeFrame: Day 14
measure: Return to room air
timeFrame: Day 14
Secondary outcomes:
measure: SARS-CoV-2 RNA
timeFrame: 28 days
measure: Discharge
timeFrame: Days 14, 21, 28
measure: Death
timeFrame: Day 14, 21, 28
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Renmin Hospital of Wuhan University
name: Zuojiong Gong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03056989: A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Official title: A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cystic Fibrosis
Lead sponsor: Spyryx Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2017-02-17
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of CF
* FEV1 ≥ 40% predicted normal
* Stable CF lung disease
* Non-pregnant, non-lactating females

Exclusion Criteria:

* Significant unstable co-morbidities within 28 days of screening as judged by the Investigator.
* Has received an investigational drug within the past 30 days

Primary outcomes:
measure: Number of participants with adverse events
timeFrame: Day 1 through Day 15
Secondary outcomes:
measure: Relative change from baseline through Day 8 in percent predicted FEV1
timeFrame: Screening and Day 1 through Day 8
measure: Change from baseline through Day 8 in clinical laboratory tests
timeFrame: Screening and Day 1 through Day 8
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Saint Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Elizabeth Tullis, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Couroux P, Farias P, Rizvi L, Griffin K, Hudson C, Crowder T, Tarran R, Tullis E. First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis. Pulm Pharmacol Ther. 2019 Oct;58:101819. doi: 10.1016/j.pupt.2019.101819. Epub 2019 Jul 11.
Clinical trial NCT00662389: Application of the Apsara Thermal Wand System
Official title: TP-1013 Pilot 1: Application of the Apsara Thermal Wand System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Tightening of Skin Laxity
Keywords: skin laxity, wrinkles, rhytids
Lead sponsor: Apsara Medical Corporation
Sponsor class: INDUSTRY
First posted: 2008-04-21
Enrollment: 4
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this feasibility study is to gain an initial assessment of the acute safety and performance of the Apsara Thermal Wand System in human facial tissue.


Eligibility criteria: Inclusion Criteria:

* Nonsmoker
* Glogau class 1-3
* Previously chosen to undergo facelift

Exclusion Criteria:

* Pregnant, nursing
* Implanted electro-mechanical device
* Allergy to anesthesia or device metals
* Collagen vascular disease
* History of keloid or hypertrophic scar formation
* Uncontrolled diabetes
* Long term steroid or other immunologic inhibitor use
* Previous treatment to target area
* Does not consent to study
* Does not consent to photography or histological evaluation

Primary outcomes:
measure: Serious Adverse Events
timeFrame: Immediate
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Bryant A. Toth, MD, FACS
state: California
Study officials:
References:
Clinical trial NCT05716789: Cardiopulmonary Resuscitation in Cases of Sudden Cardiac Arrest
Official title: The Success Rate of Cardiopulmonary Resuscitation in Sudden Cardiac Arrest
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Arrest
Keywords: CPR
Success Rate
Emergency medicine
Critical care
ICU and Pain Management
Lead sponsor: Egymedicalpedia
Sponsor class: INDUSTRY
First posted: 2023-02-08
Enrollment: 75
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Determination the success rate of CPR on adults in Emergency room and predicting the factors that makes CPR is successful.

Detailed description: Cardiac arrest is a medical emergency that requires immediate cardiopulmonary resuscitation (CPR). Return of spontaneous circulation (ROSC) is a core outcome element of cardiopulmonary resuscitation (CPR) both in out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest and has been considered a standard in the evaluation of successful resuscitation.

ROSC was defined as a clinical assessment that shows signs of life comprising of a palpable pulse for at least 20 minutes or generating a blood pressure, the duration of ROSC is key element not only to the efficacy of the chain of survival but also to assess the success of resuscitation in emergency medical services (EMSs).

Worldwide CPR outcomes vary due to differences in the circumstances of cardiac arrest, availability of equipment, and performance of the CPR team. The influencing factors of CPR outcome at the emergency room (ER) are patient characteristics, early detection, immediate CPR, initial shockable rhythm, duration of CPR of less than 10 minutes and advanced cardiac life support.

In Egypt, There has been scarce studies regarding CPR and studies that measure the success rate of CPR and factors determining its success. This study aims to assess the success rate of CPR in Emergency room and factors predicting successful CPR on adults.

Eligibility criteria: Inclusion Criteria:

* Resuscitated at the ER in Al Hussein University Hospital.
* Patients Have experienced cardiac arrest.

Exclusion Criteria:

* Patient arresting and receiving CPR inside hospital's other departments.
* Signs of sure death.
* Patient with Multiple Organ Failure Syndrome (M.O.F syndrome

Primary outcomes:
measure: CPR Success Rate
timeFrame: From base line to 20 minutes.
Secondary outcomes:
measure: predictors of Return of spontaneous circulation(ROSC)
timeFrame: from base line to 8 hoiurs
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Alhusein Hospital
Study officials:
affiliation: Al-Azhar University, Faculty of medicine for boys
name: Ahmed Mohamed Abdelgaleel, Professor
role: STUDY_CHAIR
References: